Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.51 |
| ▸ | CETP | P11597 | 3/20 | 0.47 |
| ▸ | HRAS | P01112 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9781675 | 1.00 | SIGMAR1 (0.51) | SIGMAR1CETPHRASHPGDMEN1 | |
| SCHEMBL12802756 | 1.00 | SIGMAR1 (0.51) | SIGMAR1CETPHRASHPGDMEN1 | |
| SCHEMBL8893077 | 1.00 | SIGMAR1 (0.51) | SIGMAR1CETPHRASHPGDMEN1 | |
| SCHEMBL28034249 | 1.00 | SIGMAR1 (0.51) | SIGMAR1CETPHRASHPGDMEN1 | |
| SCHEMBL28034352 | 1.00 | SIGMAR1 (0.51) | SIGMAR1CETPHRASHPGDMEN1 | |
| SCHEMBL27753131 | 0.98 | SIGMAR1 (0.53) | SIGMAR1CETPHRASHPGDMEN1 | |
| Hydrochloric Acid SCHEMBL7870266 | 0.91 | SIGMAR1 (0.44) | SIGMAR1CETPHRASHPGDMEN1 | |
| SCHEMBL437919 | 0.91 | MAOA (0.48) | SIGMAR1HRAS | |
| SCHEMBL1240611 | 0.85 | HRAS (0.46) | SIGMAR1HRASALDH1A1 | |
| SCHEMBL8863637 | 0.82 | MAOA (0.47) | SIGMAR1HRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422233-B2 | Vanilloid fatty hydroxamates as therapeutic anti-inflammatory pharmaceuticals | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-08-23 | — | — | US | disclosed |
| US-20120252891-A1 | Vanilloid Fatty Hydroxamates as Therapeutic Anti-inflammatory Pharmaceuticals | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-10-04 | — | — | US | disclosed |
| US-4987253-A | Method for the synthesis of desferrioxamine B and analogs thereof | UNIVERSITY OF FLORIDA (US) | 1991-01-22 | — | — | US | disclosed |
| EP-0347163-A2 | Method for the synthesis of desferrioxamine B and analogs thereof, and intermediates | THE UNIVERSITY OF FLORIDA (US) | 1989-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252891-A1 | Vanilloid Fatty Hydroxamates as Therapeutic Anti-inflammatory Pharmaceuticals | FAAH, FAAH2, TRPV1 | SIGMAR1 2933/4885CETP 1301/4885HRAS 3045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.